This document provides an overview of targeted drug delivery systems. It discusses the reasons for targeted delivery to increase therapeutic effects and reduce toxicity. The ideal properties of targeted delivery carriers and approaches are described. The document outlines different carrier types including vesicular, particulate, cellular, polymeric, and macromolecular systems. It discusses levels of targeting including passive, active, dual and combination approaches. Active targeting can be achieved through ligand-mediated or physical approaches. The document provides examples to illustrate different targeting strategies and carrier types. In summary, it comprehensively reviews concepts and components of targeted drug delivery systems.
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
Introduction, biopharmaceutic factors affecting drug bioavailability, rate–limiting steps in drug absorption, physicochemical nature of the drug formulation factors affecting drug product performance
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
Introduction, biopharmaceutic factors affecting drug bioavailability, rate–limiting steps in drug absorption, physicochemical nature of the drug formulation factors affecting drug product performance
The brain is a delicate organ with many vital functions and many formidable mechanisms, isolate and protect it from the outside world. Unfortunately, the same mechanisms that prevent environmental chemicals accessing the brain also prevent the access of therapeutic chemicals. The brain is segregated from the circulating blood by a unique membranous barrier i.e the blood brain barrier.
M.pharm (Pharmaceutics) Molecular Pharmaceutics (NTDS) unit 1 part 1 Targeted Drug Delivery Systems: Concepts, Events and biological process involved in drug targeting.
Gastrointestinal tract, Mechanism of drug absorption, Factors
affecting drug absorption, pH–partition theory of drug absorption. Formulation and physicochemical factors: Dissolution rate, Dissolution process, Noyes–Whitney equation and drug dissolution, Factors affecting the dissolution rate. Gastrointestinal absorption: Role of the dosage form: Solution (elixir, syrup and solution) as a dosage form ,Suspension as a dosage form, Capsule as a dosage form, Tablet as a dosage form ,Dissolution methods ,Formulation and processing factors, Correlation of in vivo data with in vitro dissolution data. Transport model: Permeability-Solubility-Charge State and the pH Partition Hypothesis, Properties of the Gastrointestinal Tract (GIT), pH Microclimate Intracellular pH Environment, Tight Junction Complex.
Nucleic acid based therapeutic drug delivery systemtadisriteja9
Nucleic acid based Drug delivery system is one of the trending research area, which i have taken and made as Powerpoint for easy and quick learning purpose
The brain is a delicate organ with many vital functions and many formidable mechanisms, isolate and protect it from the outside world. Unfortunately, the same mechanisms that prevent environmental chemicals accessing the brain also prevent the access of therapeutic chemicals. The brain is segregated from the circulating blood by a unique membranous barrier i.e the blood brain barrier.
M.pharm (Pharmaceutics) Molecular Pharmaceutics (NTDS) unit 1 part 1 Targeted Drug Delivery Systems: Concepts, Events and biological process involved in drug targeting.
Gastrointestinal tract, Mechanism of drug absorption, Factors
affecting drug absorption, pH–partition theory of drug absorption. Formulation and physicochemical factors: Dissolution rate, Dissolution process, Noyes–Whitney equation and drug dissolution, Factors affecting the dissolution rate. Gastrointestinal absorption: Role of the dosage form: Solution (elixir, syrup and solution) as a dosage form ,Suspension as a dosage form, Capsule as a dosage form, Tablet as a dosage form ,Dissolution methods ,Formulation and processing factors, Correlation of in vivo data with in vitro dissolution data. Transport model: Permeability-Solubility-Charge State and the pH Partition Hypothesis, Properties of the Gastrointestinal Tract (GIT), pH Microclimate Intracellular pH Environment, Tight Junction Complex.
Nucleic acid based therapeutic drug delivery systemtadisriteja9
Nucleic acid based Drug delivery system is one of the trending research area, which i have taken and made as Powerpoint for easy and quick learning purpose
Hi, Intranasal drug delivery to brain is one of the amazing drug delivery systems..........
Here we can deliver even the hydrophillic drugs to brain.........
through the first and fifth cranial nerves...........
thanking you,,
Brief description of targeted drug delivery system, along with its concept and strategies for drug targeting. Advantages and disadvantages of drug targeting
Need for drug targeting.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
4. Page 4
Introduction
o Definition covers following bullet points:
☼ Selective delivery/targeting
☼ Specific site of action
☼ Eliminates non-targeted organs/systems
1
5. Page 5
Introduction
o Aimed at:
☼ Selective + Effective localization
☼ Pre-identified site
☼ ↑ Therapeutic conc.
☼ Restricted to non-specific sites
☼ Minimizing toxic effects
☼ Maximizing Therapeutic index
2
7. Page 7
Reasons
o Involves:
1. Overcoming pharmaceutical drug problems
2. Delivery specification:
The capillary bed of the active sites,
The specific type of cell (or) even an intracellular region.
Ex- tumour cells but not to normal cells,
A specific organ (or) tissues by complexing with the
carrier that recognizes the target
3
9. Page 94
Free Drug
No access,
No affinity
(Limited Effect)
Access,
Affinity
(Effect: TOXICITY)
Inactivation
Or
↓ T.E.
TARGET
SITE
NON TARGET
SITE
BIO-ENVI
FACTORS
Drug+Carrier
No access,
No affinity
(Limited Effect)Facilitated Transport
(Effect: TARGETING)
Sequestration
↑Therapeutic Avail.
TARGET
SITE
NON TARGET
SITE
BIO-ENVI
FACTORS
11. Page 11
Merits
o Simplified Drug administration protocol
o ↓ Dose of drug → Cost of therapy
o ↑ Drug conc. at target than non-target sites
o Rapid Clearance
o Immune reactions (mostly against I.V. route)
o Insufficient localization in tumor cells
o Diffusion & redistribution
5
Demerits
13. Page 13
Ideal TDDS*
1) Biochemically inert, non-toxic & non-immunogenic
2) Stability (Physical & Chemical)
3) Restricted delivery to target site/organ
4) Uniform capillary distribution at the site
5) Controlled & predictable rate of delivery
6) Drug release vs Drug action
7) ↑ Therapeutic effect
8) No – Drug leakage
9) Carrier properties
10)Cost of production
6
16. Page 16
Considerations
o Majorly, considered:
Specific properties of target cells.
Nature of markers or transport carriers or vehicles, which
convey drug to specific receptors.
Ligands and physically modulated components.
8
18. Page 18
Introduction
o Required for successful transportation of the loaded drug.
o Delivers the drug within or in the vicinity of target.
o An inherent characteristic or acquired through structural
modification
9
19. Page 19
Ideal Criteria
o Able to cross anatomical barriers
o Recognized specifically and selectively by the target cells.
o The linkage and the directing unit (ligand) should be stable in
plasma, interstitial and other bio fluids.
o Non-toxic, non-immunogenic and biodegradable particulate or
macromolecule.
o After recognition/internalization, can release the moiety.
10
20. Page 20
Types
o Based on “Nature of Origin”:
1. Endogenous (LDL ,HDL Chylomicrons, Serum albumin,
Erythrocytes)
2. Exogenous (Microparticulates, Soluble polymeric and
Biodegradable polymeric drug carriers.
11
21. Page 21
Types
o Based on Pharmaceutical approaches:
1. Colloidal carriers
2. Cellular carriers
3. Supra-molecular delivery systems
4. Polymer based systems
5. Macromolecular carriers
12
22. Page 22
Types
Vesicular systems
Ex: Liposomes, niosomes, pharmacosomes, virosomes,
immunoliposomes.
Microparticulate systems
Ex: Microparticles, Nanoparticles, Magnetic microspheres,
Albumin microspheres, Nanocapsules.
13
Colloidal Carriers
26. Page 26
Types
o Proteins, glycoproteins, Neo glycoproteins and artificial viral
envelopes (AVE).
o Glycosylated water soluble polymers (poly-L-lysine).
o Mabs, Immunological fragments, antibody enzyme complex and
bispecific Abs.
o Toxins, immunotoxin .
o Lectins and polysaccharides
17
Macro molecular
forms
29. Page 29
Levels
o Systems that target the systemic circulation.
o Devices include-
drug bearing bilayer vesicular systems
cellular carriers of micron or submicron size range.
19
Passive Targeting
30. Page 30
Levels
o Based on attempts to
- circumvent and - avoid
Passive uptake of colloidal carriers by RES, leading to reversion of bio
distribution trend of the carrier.
20
Inverse Targeting
32. Page 32
Levels
o The facilitation of the binding of the drug carrier to target cells by
the use of ligands
To increase receptor mediated localization of the drug
Target specific delivery of drug
22
Active Targeting
33. Page 33
Levels
o Orders of Active Targeting:
a. First order targeting (organ compartmentalization)
b. Second order targeting (cellular targeting)
c. Third order targeting (intracellular targeting)
23
Active Targeting
34. Page 34
Levels
o First Order:
- Restricted distribution of the drug carrier system to the capillary
bed of the predetermined target site, organ or tissue.
Ex: Compartmental targeting
*Lymphatics *Peritoneal cavity *Plural cavity
*Cerebral ventricles *Lungs, joints, eyes, etc.
24
Active Targeting
35. Page 35
Levels
o Second Order:
- Selective delivery of drugs to a specific cell types.
- Such as tumour cells (and not to the normal cells) is referred to
as second order
25
Active Targeting
36. Page 36
Levels
o Approaches for Active Targeting
- Ligand Mediated
- Physical (Triggered Release)
26
Active Targeting
37. Page 37
Levels
o Using carrier molecules, having intrinsic antiviral effect thus
synergies the antiviral effect of the loaded active drug.
Ex: drug conjugates can be prepared with fortified activity profile
against the viral replication.
Dual Targeting
• The virus replication process can be attacked at multiple points,
excluding the possibilities of resistant viral strain development.
27
38. Page 38
Levels
o To achieve a double targeting effect,
site specificity of the drug,
by virtue of targeting moiety,
a high specificity module (mainly a photosensitizer) is
linked to antibodies.
28
Double Targeting
39. Page 39
Levels
o Firstly, suggested by Petit and Gombtz.
o Focussed on Site-specific delivery of proteins and peptides.
29
Combination
Targeting
42. Page 42
Approaches
1. Targeting to the mononuclear phagocytic system (MPS):
I.V. administered liposomes—localize within MPS.
MPS consists of connective tissues of mesenchymal origin.
Physical
• Clearance of large variety of harmful substances from plasma.
• Catabolism of macromolecules.
• Participation in immune response.
• Synthesis and secretion of various effector molecules.
• Targeting of AZIDOTHYMIDINE (AZT) to macrophages as
nanoparticle carriers by I.V. & oral routes.
• Liposomal delivery of certain compounds may provide
extended retention.
• Liposomal delivery of drugs systemically enhances drug
concentration of antimicrobials.
31
43. Page 43
Approaches
2. Targeting to the Pulmonary region
- Diagnostic purposes
3. Extravascular systems
- anticancer drug camptothecin + nanoparticles = ↑ avg
residence time.
4. Mucosal delivery of antigens
- microspheres of Staphylococcal enterotoxin B toxoid.
32
Physical
44. Page 44
Approaches
o Involves delivery of the drug using carrier system with targeting
moiety
either in-built (by virtue of the structure of the carrier) or
is chemically coupled.
Biological
• Antibodies directed against specific cell surface antigens,
• Endogenous carbohydrate-binding proteins (lectins).
• Glycoconjugates functioning as specific ligands for receptors
on specific cells that recognize particular sugar residues, and
• Hormones functioning as specific ligands for receptors on
specific targets.
• Ex:
1. Coupling of viral antigens to monoclonal antibodies against
a mouse Class II MHC.
2. Naproxen using lysozyme as carrier (since it is taken up &
catabolized in (PCT) - Showed 70 fold ↑ in retention.
3. Insulin used as enzyme carrier for correcting enzyme
deficiency disease in fibroblasts from patients with
cholesterol storage disease.
33
45. Page 45
Approaches
o Incorporates targeting consideration into the drug design
process—for design of safe, localized delivery.
o Targeting to active biological molecules based on predictable
enzymatic activation.
o Allow sustained release of drugs too.
Chemical
• Ex:
1. Drug targeting to lungs
2. Drug targeting to brain
3. Osteotropic DD
34
47. Page 47
References
o Drug Targeting Organ-Specific Strategies Edited by Grietje Molema
and Dirk K. F. Meijer, 2007.
o Targeted and Controlled drug delivery (Novel carrier systems), S P
Vyas and R K Khar, CBS publishers, 2002.
o Progress in Controlled and Novel drug delivery systems by N K
Jain, CBS publishers, 2008.
35
2. Both invitro n invivo
8. During transit
10. easy,simple,reroducible
A cell or grp of cell in minority, identified to be in need of treatment
Are vector which sequester, retain drug & transport or deliver it into d vicinity of target.
Confer recognition & specificity upon carrier/vector & guide them.
A cell or grp of cell in minority, identified to be in need of treatment
Are vector which sequester, retain drug & transport or deliver it into d vicinity of target.
Confer recognition & specificity upon carrier/vector & guide them.
and in case of tumour chemotherapy tumour vasculature.
and must maintain the specificity of the surface ligands.
1. suppressed by a pre-injection of colloidal carriers or macromolecules like dextran sulphate
2.modification of the size, surface charge,composition, surface rigidity & hydrophilicity of carriers for desirable biofate.
receptor dependent uptake of natural LDL particles and synthetic lipid microemulsions of partially reconstituted LDL particles coated with the apoproteins
drug delivery programmed and monitored at the external level (ex vivo) with the help of physical means (=ex)